Leukapheresis Market

Leukapheresis Market by Product (Devices, Filters, Columns, Disposables), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) - Global Forecast to 2026

Report Code: MD 6538 Apr, 2021, by marketsandmarkets.com

[247 Pages Report] The global leukaphereis products market is projected to reach USD 91 million by 2026 from USD 61 million in 2021, at a CAGR of 8.4% during the forecast period. The leukopaks market is expected to reach USD 662 million by 2026, at a CAGR of 41.9%. Leukopaks are enriched leukapheresis products that contain higher concentrations of leukocytes. The increasing incidence and prevalence of leukemia and growing demand for leukopaks for research applications are some of the factors driving the growth of these markets. However, the high cost of therapeutic leukapheresis and cellular therapies, stringent donor recruitment criteria, and long procedural time for leukapheresis are restraining the growth of this market to a certain extent.

Leukapheresis Market

To know about the assumptions considered for the study, download the pdf brochure

Covid-19 Impact on the Leukapheresis Products and Leukopaks Market

In the optimistic scenario, it could be assumed that the pandemic has created a positive impact on the leukapheresis market. The ongoing clinical trials for COVID-19 vaccines could positively impact the leukapheresis products market, as the study of white blood cells is integral in supporting vaccine development. Moreover, some studies are also being carried out to understand the overall effect of COVID-19 on white blood cells. For instance, the NIH is conducting clinical trials that require leukapheresis to understand the effect of SARS-CoV-2 on lymphocytes. In the pessimistic scenario, it could be assumed that the COVID-19 pandemic has drastically lowered the demand for leukapheresis, especially for research purposes, and also reduced the demand for leukopaks. Therapeutic leukapheresis could be classified under essential procedures and, hence, would have resumed early post the stringent regulations, which were imposed in the first and second quarter of 2020 in many parts of the world. However, clinical trials were disrupted during this period and have not fully recovered in the post-lockdown period. This could affect the future demand for leukopaks in the pessimistic scenario.

Leukapheresis Products and Leukopaks Market Dynamics

Driver: Increasing incidence and prevalence of leukemia

Globally, the incidence of leukemia has risen significantly. According to the American Cancer Society, in 2021, there will be an estimated 61,090 new cases of leukemia in the US. It is also estimated that there will be an estimated 23,660 deaths in 2021 due to leukemia in the US. The incidence rate of leukemia in children has increased by 1% year-on-year from 2008 to 2020. It can be inferred that the rising incidence of hyperleukocytic leukemia will drive the number of therapeutic leukapheresis procedures conducted in the coming years and, thereby, support the growth of the leukapheresis market.

Restraint: High cost of therapeutic leukapheresis and leukopaks

The average price for apheresis devices ranges between USD 20,000 and USD 150,000. Hence, smaller blood banks and hospitals do not opt for this type of blood collection. Furthermore, qualified and skilled physicians/labor/nurses are also required for effective treatment and the collection/removal of WBCs using apheresis. All these factors make leukapheresis an expensive tool for short-term use. Similarly, the cost of leukapheresis at hospitals and cancer treatment centers is also very high as it incurs the additional cost of disposables—between USD 1,500 and USD 3,000 per patient. Therefore, the adoption of leukapheresis and leukopaks among small blood banks, research centers, and hospitals is very low, which, in turn, will restrain the growth of the leukapheresis market during the forecast period.

Opportunity: Leukapheresis for pediatric patients

Despite its therapeutic applications, the adoption of leukapheresis as a treatment, particularly for hyperleukocytic leukemia, is still low. However, the applications of therapeutic leukapheresis in the treatment of pediatric patients are becoming an area of focus for stakeholders in this sector. This can be mainly attributed to the side-effects and risks of conventional treatments such as chemotherapy for children. Leukapheresis can be used for both the treatment/removal of excess WBCs in pediatric lymphoma patients and the collection of stem cells from children for other cancer patients. The possibilities and advantages of leukapheresis in this application make it an area of focus in this market, particularly given that very few hospitals currently provide leukapheresis treatment for children in both developed as well as emerging markets.

Challenge: Blood transfusion safety in developing countries

WBC transfusions have associated risks of transmitting infectious agents such as HIV, HBV, HCV, and malaria. Infection through the blood supply is a major issue, especially in developing countries such as India, China, Brazil, and Argentina, where economic constraints often limit safety considerations during WBC transfusion procedures.
Testing blood for HIV and hepatitis B viruses is an integral part of the blood transfusion process across the globe; moreover, the necessity of this step is more pronounced in developing countries where the burden of these diseases is higher. Thus, ensuring blood safety is a major challenge faced by blood and blood component suppliers and healthcare institutions in developing countries.

The leukapheresis devices segment is expected to grow at the highest CAGR, in the leukapheresis products market by type, in the forecast period

Leukapheresis devices are used for the separation of white blood cells (leukocytes) from whole blood. These instruments are also used to develop leukoreduced blood cell products such as leukoreduced plasma and leukoreduced RBCs. The growth of the leukapheresis devices market can largely be attributed to the increasing number of therapeutic leukapheresis procedures conducted for the treatment of leukemia, immune-mediated inflammatory diseases, and inflammatory bowel diseases. The increasing adoption of leukapheresis instruments by blood collection centers is another major factor supporting market growth.

The centrifugal devices segment holds the largest share in the leukapheresis devices segment, in the forecast period.

The centrifugal devices segment holds the largest share in the leukapheresis devices segment in the forecast period. The increasing installation of centrifugal apheresis devices in hospitals for therapeutic apheresis, favorable reimbursement policies for therapeutic apheresis, and the increasing use of centrifugal apheresis for blood component donations by blood centers and hospitals are the major factors driving the growth of the centrifugal apheresis devices market. However, the higher cost of continuous apheresis in comparison with membrane separation is limiting the growth of this market to a certain extent.

Research applications is expected to grow at the highest CAGR in the leukapheresis products by application segment in the forecast period.

The research applications segment is expected to grow at the highest CAGR in the leukapheresis products, by application segment in the forecast period. The large share of this segment is attributed to the increasing adoption of leukapheresis products for the development of cell-based immunotherapies, the increasing and the increasing number of clinical trials using leukopaks as a starting raw material for the development of cell-based therapies.

In 2020, the blood component providers & blood centers segment accounted for the largest share of the leukapheresis products market

The blood component providers & blood centers segment accounted for the largest share of the leukapheresis products market in 2020.  The high share of this segment can be attributed to the increasing number of blood donations, growing demand for leukopaks for the development of CAR T-cell therapies, and the increasing demand for blood components in clinical conditions such as cancer.

The mobilized leukopaks segment accounted for the largest share of the leukopaks market, by type, in the forecast period.

Based type, the mobilized leukopaks segment accounted for the largest share of the leukopaks market in the forecast period. The large share of this segment can be attributed to the increasing demand for low-granulocyte and low-hematocrit contamination, high cell viability, and an increase in CD34+ cell frequencies for the development of immunotherapies.

The pancreatic cancer segment is growing at the highest CAGR in the leukopaks market, by application, in the forecast period.

Based on application, the pancreatic cancer segment is expected to grow at the highest CAGR in the forecast period. The high growth of this segment can be attributed to the high potential of CAR T Cell therapy in pancreatic cancer including its ability to be directed against novel epitopes and combined with other therapeutic regimens for the disease.

Asia Pacific is growing at the highest CAGR in the leukapheresis products and leukopaks market, by region in the forecast period.

The Asia Pacific is growing at the highest CAGR in the leukapheresis products and leukopaks market, by region in the forecast period. This high growth can be attributed to emerging markets in the Asia Pacific becoming prominent growth hotspots in the market due to factors such as the rising geriatric population, the growing prevalence of leukemia, improving healthcare infrastructure, increasing number of clinical trials in China, and increasing public and private investments for the development of CAR-T therapy.

Leukapheresis Market  by Region

Key Market Players

Key players in the leukapheresis products and leukopaks market: Asahi Kasei Medical Co. Ltd. (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), Miltenyi Biotec (Germany), Guangzhou Daji Medical Science and Technology Co. Ltd. (China), MEDICA S.p.A (Italy), PuriBlood Medical Co. Ltd. (Taiwan), and Beijing ZKSK Technology Co. Ltd. (China). Some prominent players in the leukopaks market are Charles River Laboratories (US), AllCells, LLC (US), StemExpress, LLC. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), ZenBio (US), Precision for Medicine (US), BioIVT (US), Discovery Life Sciences (US), and Intelligent Tissue Group (US).

The prominent players in the global leukapheresis products and leukopaks market are

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market Size available for years

2019-2026

Base Year Considered

2020

Forecast period

2021-2026

Forecast Unit

Value (USD Million)

Segments covered

Leukapheresis Products Market:
Type, Application, End User
Leukopaks Market:
Type, Indication, End User

Geographies covered

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • Spain
    • Rest of Europe(RoE)
  • Asia Pacific
    • China
    • Japan
    • Rest of Asia Pacific (RoAPAC)
  • Rest of the World

Companies Covered

Asahi Kasei Medical Co. Ltd. (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), Miltenyi Biotec (Germany), Guangzhou Daji Medical Science and Technology Co. Ltd. (China), MEDICA S.p.A (Italy), PuriBlood Medical Co. Ltd. (Taiwan), and Beijing ZKSK Technology Co. Ltd. (China). Some prominent players in the leukopaks market are Charles River Laboratories (US), AllCells, LLC (US), StemExpress, LLC. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), ZenBio (US), Precision for Medicine (US), BioIVT (US), Discovery Life Sciences (US), and Intelligent Tissue Group (US).

The research report categorizes the market into the following segments and subsegments:

Leukapheresis Products Market, By Type

  • Leukapheresis Disposables
  • Leukapheresis Devices
    • Centrifugal Devices
    • Membrane Separators

Leukapheresis Products Market, By Application

  • Research Applications
  • Therapeutic Applications

Leukapheresis Products Market, By End User

  • Blood Component Providers & Blood Centers
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Hospital & Transfusion Centers

Leukopaks Market, By Type

  • Mobilized Leukopaks
  • Non-Mobilized Leukopaks
  •  Diseased Leukopaks
  • Isolated PBMCs

Leukopaks Market, By Application

  • Mobilized Leukopaks
  • Non-Mobilized Leukopaks
  •  Diseased Leukopaks
  • Isolated PBMCs

Leukopaks Market, By Indication

  • Acute Lymphocytic Leukemia
  • Multiple Myeloma
  •  Non-Hodgkin’s Lymphoma
  • Chronic Lymphocytic Lymphoma
  • Pancreatic Cancer
  • Hepatocellular Carcinoma
  • Other Indications

Leukopaks Market, By End User

  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations

Leukaphersis Products and Leukopaks Market, by Region

  • North America
    • US
    • Canada        
  • Europe
    • UK
    • Germany
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Rest of the World

Recent Developments:

  • In September 2020, AllCells, LLC. (US) added cryopreserved leukopaks to its product portfolio to ensure access to high-quality primary cells without potential delivery delays.
  • In June 2020, Haemonetics Corporation (US), announced an agreement to sell its Fajardo, Puerto Rico manufacturing operations of blood filters to GVS S.p.A. (Italy).
  • In June 2020, StemExpress, LLC. (US) added frozen leukopaks, LE00 (2.5C, 5C, 10C), which are frozen after fresh blood collection and provide an enriched source of peripheral blood mononuclear cells for medical research.
  • In January 2020, Fresenius Kabi (Germany) inaugurated the expansion of its transfusion and apheresis disposables plant in the Dominican Republic in Santa Domingo.
  • In February 2019, Terumo BCT, Inc. (US) expanded its global footprint by opening its first regional office in sub-Saharan Africa, in Nairobi, Kenya.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 30)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
           TABLE 1 STANDARD CURRENCY CONVERSION RATES
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 36)
    2.1 RESEARCH DATA
           FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
           FIGURE 2 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Insights from primary experts
           FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS (LEUKAPHERESIS & LEUKOPAKS MARKET)
           FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION, AND REGION (LEUKAPHERESIS MARKET)
           FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (LEUKOPAKS MARKET)
    2.2 MARKET SIZE ESTIMATION: LEUKAPHERESIS MARKET
           FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
           FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION
           FIGURE 8 REVENUE ANALYSIS OF THE TOP 4 COMPANIES: LEUKAPHERESIS MARKET (2020)
           FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS (LEUKAPHERESIS MARKET)
           FIGURE 10 TOP-DOWN APPROACH
    2.3 MARKET SIZE ESTIMATION: LEUKOPAKS MARKET
           FIGURE 11 VOLUME ESTIMATION OF LEUKOPAKS MARKET
           FIGURE 12 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS (LEUKOPAKS MARKET)
           FIGURE 13 TOP-DOWN APPROACH
    2.4 MARKET BREAKDOWN & DATA TRIANGULATION
           FIGURE 14 MARKET DATA TRIANGULATION METHODOLOGY
    2.5 MARKET SHARE ANALYSIS
    2.6 ASSUMPTIONS FOR THE STUDY
    2.7 RISK ASSESSMENT
           TABLE 2 RISK ASSESSMENT: LEUKAPHERESIS & LEUKOPAKS MARKET
    2.8 COVID-19 HEALTH ASSESSMENT
    2.9 COVID-19 ECONOMIC ASSESSMENT
    2.10 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
           FIGURE 15 CRITERIA IMPACTING THE GLOBAL ECONOMY
           FIGURE 16 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
    2.11 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE LEUKAPHERESIS AND LEUKOPAKS MARKET

3 EXECUTIVE SUMMARY (Page No. - 57)
           FIGURE 17 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
           FIGURE 18 LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
           FIGURE 19 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
           FIGURE 20 LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
           FIGURE 21 LEUKOPAKS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
           FIGURE 22 LEUKOPAKS MARKET, BY INDICATION, 2021 VS. 2026 (USD MILLION)
           FIGURE 23 LEUKOPAKS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
           FIGURE 24 GEOGRAPHIC SNAPSHOT: LEUKAPHERESIS PRODUCTS MARKET
           FIGURE 25 GEOGRAPHIC SNAPSHOT: LEUKOPAKS MARKET

4 PREMIUM INSIGHTS (Page No. - 63)
    4.1 LEUKAPHERESIS PRODUCTS MARKET OVERVIEW
           FIGURE 26 INCREASING INCIDENCE AND PREVALENCE OF LEUKEMIA TO DRIVE MARKET GROWTH
    4.2 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE AND COUNTRY
           FIGURE 27 LEUKAPHERESIS DISPOSABLES COMMANDED THE LARGEST SHARE OF THE NORTH AMERICAN LEUKAPHERESIS PRODUCTS MARKET IN 2020
    4.3 LEUKAPHERESIS PRODUCTS MARKET: GEOGRAPHIC MIX
           FIGURE 28 CHINA TO WITNESS THE HIGHEST GROWTH IN THE LEUKAPHERESIS PRODUCTS MARKET DURING THE FORECAST PERIOD
    4.4 REGIONAL MIX: LEUKAPHERESIS PRODUCTS MARKET
           FIGURE 29 NORTH AMERICA DOMINATED THE MARKET IN 2020
    4.5 LEUKOPAKS MARKET OVERVIEW
           FIGURE 30 FAVORABLE GOVERNMENT SUPPORT AND RISING DEMAND FOR LEUKOPAKS IN RESEARCH APPLICATIONS TO DRIVE MARKET GROWTH
    4.6 NORTH AMERICA: LEUKOPAKS MARKET, BY PRODUCT AND COUNTRY
           FIGURE 31 MOBILIZED LEUKOPAKS COMMANDED THE LARGEST SHARE OF THE NORTH AMERICAN LEUKOPAKS MARKET IN 2020
    4.7 LEUKOPAKS MARKET: GEOGRAPHIC MIX
           FIGURE 32 CHINA TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
    4.8 REGIONAL MIX: LEUKOPAKS MARKET
           FIGURE 33 APAC MARKET TO WITNESS THE HIGHEST GROWTH

5 MARKET OVERVIEW (Page No. - 68)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 34 LEUKAPHERESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 MARKET DRIVERS
                    5.2.1.1 Increasing incidence and prevalence of leukemia
           FIGURE 35 INCIDENCE AND MORTALITY RATES OF LEUKEMIA, BY REGION, 2020
                    5.2.1.2 Increasing number of blood donations
           TABLE 3 COLLECTION OF WHOLE BLOOD UNITS, BY COUNTRY, 2015–2016 (MILLION UNITS)
                    5.2.1.3 Demand for leukopaks in clinical research
           FIGURE 36 GROWTH IN THE NUMBER OF CAR-T CLINICAL TRIALS
           5.2.2 MARKET RESTRAINTS
                    5.2.2.1 High cost of therapeutic leukapheresis and leukopaks
           TABLE 4 COST OF LEUKOPAKS, BY TYPE
                    5.2.2.2 Stringent donor recruitment criteria
           TABLE 5 DONOR SELECTION CRITERIA
           TABLE 6 FREQUENCY OF BLOOD DONATIONS FROM HEALTHY DONORS
                    5.2.2.3 Dearth of skilled professionals and low adoption of therapeutic leukapheresis
                    5.2.2.4 Complications associated with therapeutic leukapheresis
                    5.2.2.5 Long procedural time for leukapheresis
                    5.2.2.6 High cost of cellular immunotherapies & lack of favorable reimbursement
           5.2.3 MARKET OPPORTUNITIES
                    5.2.3.1 Leukapheresis for pediatric patients
                    5.2.3.2 Emerging economies and increasing investments from academic institutes, pharma-biotech companies, and leading players
           5.2.4 MARKET CHALLENGES
                    5.2.4.1 Blood transfusion safety in developing countries
    5.3 PORTER’S FIVE FORCES ANALYSIS
           FIGURE 37 PORTER’S FIVE FORCES ANALYSIS (2020): LEUKAPHERESIS MARKET
           TABLE 7 LEUKAPHERESIS MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.3.1 THREAT FROM NEW ENTRANTS
           5.3.2 THREAT FROM SUBSTITUTES
           5.3.3 BARGAINING POWER OF SUPPLIERS
           5.3.4 BARGAINING POWER OF BUYERS
           5.3.5 INTENSITY OF COMPETITIVE RIVALRY
    5.4 LEUKOPAKS: PRICING ANALYSIS
           TABLE 8 ASP OF NON-MOBILIZED LEUKOPAKS
           TABLE 9 ASP OF MOBILIZED LEUKOPAKS
           TABLE 10 ASP OF MOBILIZED ISOLATED CELLS
    5.5 REGULATORY ANALYSIS (LEUKAPHERESIS PRODUCTS MARKET)
           5.5.1 NORTH AMERICA
                    5.5.1.1 US
                    5.5.1.2 Canada
           5.5.2 EUROPE
           5.5.3 ASIA PACIFIC
                    5.5.3.1 Japan
    5.6 REGULATORY ANALYSIS (LEUKOPAKS MARKET)
           5.6.1 US
           TABLE 11 LIST OF FDA-APPROVED CAR-T THERAPEUTICS
           5.6.2 EUROPE
           5.6.3 JAPAN
           5.6.4 CHINA
           5.6.5 INDIA
    5.7 VALUE CHAIN ANALYSIS
           FIGURE 38 VALUE CHAIN: LEUKAPHERESIS MARKET (LEUKAPHERESIS SYSTEMS)
    5.8 ECOSYSTEM MAP
           TABLE 12 LEUKAPHERESIS MARKET: ECOSYSTEM
           FIGURE 39 LEUKAPHERESIS MARKET: ECOSYSTEM MAP (2020)
    5.9 PATENT ANALYSIS
           5.9.1 PATENT PUBLICATION TRENDS IN THE LEUKAPHERESIS MARKET
           FIGURE 40 GLOBAL PATENT PUBLICATION TRENDS IN THE LEUKAPHERESIS MARKET, 2015–2020
           5.9.2 TOP APPLICANTS (COMPANIES) FOR LEUKAPHERESIS PATENTS
           FIGURE 41 TOP APPLICANT COMPANIES FOR LEUKAPHERESIS PATENTS, 2015–2020
           5.9.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR LEUKAPHERESIS MARKET PATENTS
           FIGURE 42 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR LEUKAPHERESIS PATENTS, 2015–2020
    5.10 TECHNOLOGY ANALYSIS
           5.10.1 KEY MARKETS FOR IMPORT AND EXPORT (TRADE ANALYSIS FOR APHERESIS-RELATED PRODUCTS & EQUIPMENT)
                    5.10.1.1 US
           TABLE 13 US: NUMBER OF EXPORTS RELATED TO APHERESIS PRODUCTS
                    5.10.1.2 Russia
           TABLE 14 RUSSIA: NUMBER OF EXPORTS RELATED TO APHERESIS PRODUCTS
                    5.10.1.3 China
           TABLE 15 CHINA: NUMBER OF EXPORTS RELATED TO APHERESIS PRODUCTS

6 INDUSTRY INSIGHTS (Page No. - 92)
    6.1 INTRODUCTION
    6.2 INDUSTRY TRENDS
           6.2.1 INCREASING NUMBER OF COLLABORATIONS AMONG PHARMA AND BIOTECH COMPANIES
           TABLE 16 RECENT PHARMA-BIOTECH COLLABORATIONS FOR CAR-T THERAPY
           6.2.2 INTRODUCTION OF CUSTOMIZABLE CRYOPRESERVED LEUKOPAKS
           6.2.3 USE OF LEUKAPHERESIS IN CLINICAL TRIALS TO DETERMINE CHANGES IN CELLULAR IMMUNE PROFILES IN COVID-19 INFECTIONS

7 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE (Page No. - 95)
    7.1 INTRODUCTION
           TABLE 17 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 18 LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.2 LEUKAPHERESIS DISPOSABLES
           7.2.1 RECURRENT USAGE AND DEMAND FOR DISPOSABLES BOOSTING THE GROWTH OF THIS SEGMENT
           TABLE 19 MANUFACTURERS OF LEUKOREDUCTION FILTERS
           TABLE 20 MANUFACTURERS OF LEUKAPHERESIS COLUMNS & CELL SEPARATORS
           TABLE 21 LEUKAPHERESIS DISPOSABLES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.3 LEUKAPHERESIS DEVICES
           TABLE 22 LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 23 LEUKAPHERESIS DEVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           7.3.1 CENTRIFUGAL DEVICES
                    7.3.1.1 Increasing installation of centrifugal apheresis devices in hospitals for therapeutic apheresis to drive market growth
           TABLE 24 LIST OF CENTRIFUGAL APHERESIS DEVICES AVAILABLE IN THE MARKET
           TABLE 25 CENTRIFUGAL APHERESIS DEVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           7.3.2 MEMBRANE SEPARATORS
                    7.3.2.1 Difficulties in separating huge volumes of plasma from milliliters of whole blood—a key factor limiting the adoption of these devices
           TABLE 26 LIST OF MEMBRANE SEPARATORS AVAILABLE IN THE MARKET
           TABLE 27 MEMBRANE SEPARATORS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

8 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION (Page No. - 104)
    8.1 INTRODUCTION
           TABLE 28 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
    8.2 RESEARCH APPLICATIONS
           8.2.1 INCREASING NUMBER OF CLINICAL TRIALS TO DRIVE THE GROWTH OF THIS SEGMENT
           TABLE 29 LEUKAPHERESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
    8.3 THERAPEUTIC APPLICATIONS
           8.3.1 INCREASING ADOPTION OF LEUKAPHERESIS PROCEDURES AS A SUPPORTIVE TREATMENT IN LEUKEMIA TO DRIVE MARKET GROWTH
           TABLE 30 LEUKAPHERESIS PRODUCTS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2019–2026 (USD THOUSAND)

9 LEUKAPHERESIS PRODUCTS MARKET, BY END USER (Page No. - 108)
    9.1 INTRODUCTION
           TABLE 31 LEUKAPHERESIS PRODUCTS MARKET, BY END USER,2019–2026 (USD MILLION)
    9.2 BLOOD COMPONENT PROVIDERS & BLOOD CENTERS
           9.2.1 BLOOD COMPONENT PROVIDERS & BLOOD CENTERS ARE THE LARGEST END USERS OF LEUKAPHERESIS PRODUCTS
           TABLE 32 LEUKAPHERESIS PRODUCTS MARKET FOR BLOOD COMPONENT PROVIDERS & BLOOD CENTERS, BY COUNTRY, 2019–2026 (USD MILLION)
    9.3 ACADEMIC & RESEARCH INSTITUTES
           9.3.1 COLLABORATIONS BETWEEN PHARMACEUTICAL COMPANIES AND ACADEMIC & RESEARCH INSTITUTES WILL DRIVE MARKET GROWTH
           TABLE 33 LEUKAPHERESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
    9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
           9.4.1 INCREASING NUMBER OF CLINICAL TRIALS TO DRIVE THE GROWTH OF THIS END-USER SEGMENT
           TABLE 34 LEADING PHARMA-BIOTECH COMPANIES INVOLVED IN THE DEVELOPMENT OF CAR T-CELL TECHNOLOGIES
           TABLE 35 LEUKAPHERESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
    9.5 HOSPITALS & TRANSFUSION CENTERS
           9.5.1 GROWTH IN THE NUMBER OF HOSPITALS PERFORMING TRANSFUSION TO DRIVE MARKET GROWTH
           TABLE 36 LEUKAPHERESIS PRODUCTS MARKET FOR HOSPITALS & TRANSFUSION CENTERS, BY COUNTRY, 2019–2026 (USD MILLION)

10 LEUKOPAKS MARKET, BY TYPE (Page No. - 115)
     10.1 INTRODUCTION
           TABLE 37 LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 38 LEUKOPAKS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
     10.2 MOBILIZED LEUKOPAKS
             10.2.1 MOBILIZED LEUKOPAKS ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET
           TABLE 39 MOBILIZED LEUKOPAKS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 40 MOBILIZED LEUKOPAKS MARKET, BY REGION, 2019–2026 (UNITS)
     10.3 NON-MOBILIZED LEUKOPAKS
             10.3.1 LOW COST AS COMPARED TO MOBILIZED LEUKOPAKS TO DRIVE MARKET GROWTH
           TABLE 41 COMPARATIVE ANALYSIS OF MOBILIZED LEUKOPAKS AND NON-MOBILIZED LEUKOPAKS
           TABLE 42 NON-MOBILIZED LEUKOPAKS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 43 NON-MOBILIZED LEUKOPAKS MARKET, BY REGION, 2019–2026 (UNITS)
     10.4 DISEASED LEUKOPAKS
             10.4.1 RISING ADOPTION OF DISEASED LEUKOPAKS FOR CELL INTERACTION AND DRUG TOXICITY STUDIES TO DRIVE MARKET GROWTH
           TABLE 44 DISEASED LEUKOPAKS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 45 DISEASED LEUKOPAKS MARKET, BY REGION, 2019–2026 (UNITS)
     10.5 ISOLATED PBMCS
             10.5.1 INCREASING FOCUS OF RESEARCHERS ON CELL-BASED THERAPIES TO DRIVE MARKET GROWTH
           TABLE 46 ISOLATED PBMCS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 47 ISOLATED PBMCS MARKET, BY REGION, 2019–2026 (UNITS)

11 LEUKOPAKS MARKET, BY INDICATION (Page No. - 124)
     11.1 LEUKOPAKS MARKET, BY INDICATION
           FIGURE 43 GLOBAL NUMBER OF CLINICAL TRIALS WITH CHIMERIC ANTIGEN RECEPTOR CELLS
           TABLE 48 LEUKOPAKS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
           TABLE 49 LEUKOPAKS MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2019–2026 (USD MILLION)
           TABLE 50 LEUKOPAKS MARKET FOR MULTIPLE MYELOMA, BY REGION, 2019–2026 (USD MILLION)
           TABLE 51 LEUKOPAKS MARKET FOR NON-HODGKIN’S LYMPHOMA, BY REGION, 2019–2026 (USD MILLION)
           TABLE 52 LEUKOPAKS MARKET FOR CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2019–2026 (USD MILLION)
           TABLE 53 LEUKOPAKS MARKET FOR PANCREATIC CANCER, BY REGION, 2019–2026 (USD MILLION)
           TABLE 54 LEUKOPAKS MARKET FOR HEPATOCELLULAR CARCINOMA, BY REGION, 2019–2026 (USD MILLION)
           TABLE 55 LEUKOPAKS MARKET FOR OTHER INDICATIONS, BY REGION, 2019–2026 (USD MILLION)

12 LEUKOPAKS MARKET, BY END USER (Page No. - 129)
     12.1 INTRODUCTION
           TABLE 56 LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION)
     12.2 ACADEMIC & RESEARCH INSTITUTES
             12.2.1 INCREASING NUMBER OF INDUSTRY-ACADEMIC PARTNERSHIPS FOR CONDUCTING RESEARCH ON CELL-BASED CANCER THERAPIES TO DRIVE MARKET GROWTH
           TABLE 57 LEUKOPAKS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
     12.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
             12.3.1 RISING DEMAND FOR TARGET DRUG DEVELOPMENT UTILIZING LEUKOPAKS AS STARTING MATERIAL TO DRIVE MARKET GROWTH
           TABLE 58 LEUKOPAKS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
     12.4 CONTRACT RESEARCH ORGANIZATIONS
             12.4.1 INCREASING SPONSORSHIP OF CLINICAL TRIALS TO DRIVE THE GROWTH OF THIS END-USER SEGMENT
           TABLE 59 LEUKOPAKS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019–2026 (USD MILLION)

13 GEOGRAPHIC ANALYSIS (Page No. - 134)
     13.1 INTRODUCTION
           FIGURE 44 LEUKAPHERESIS PRODUCTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           TABLE 60 LEUKAPHERESIS PRODUCTS MARKET, BY REGION, 2019–2026 (USD MILLION)
           FIGURE 45 LEUKOPAKS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           TABLE 61 LEUKOPAKS MARKET, BY REGION, 2019–2026 (USD MILLION)
     13.2 NORTH AMERICA
           FIGURE 46 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT
           TABLE 62 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 63 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 64 NORTH AMERICA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 65 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 66 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2019–2026 (USD MILLION)
           TABLE 67 NORTH AMERICA: LEUKOPAKS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 68 NORTH AMERICA: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 69 NORTH AMERICA: LEUKOPAKS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
           TABLE 70 NORTH AMERICA: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION)
             13.2.1 US
                        13.2.1.1 The presence of a large number of leading pharmaceutical and biotechnology companies to drive market growth in the US
           FIGURE 47 NUMBER OF REGISTERED CAR THERAPY CLINICAL TRIALS IN THE US, 2013–2020
           TABLE 71 US: KEY MACROINDICATORS
           TABLE 72 US: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 73 US: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 74 US: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 75 US: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2019–2026 (USD MILLION)
           TABLE 76 US: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 77 US: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION)
             13.2.2 CANADA
                        13.2.2.1 Rising prevalence of blood cancer to stimulate market growth in Canada
           TABLE 78 CANADA: KEY MACROINDICATORS
           TABLE 79 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 80 CANADA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2019–2026 (USD THOUSAND)
           TABLE 81 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2019–2026 (USD THOUSAND)
           TABLE 82 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2019–2026 (USD THOUSAND)
           TABLE 83 CANADA: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 84 CANADA: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION)
     13.3 EUROPE
           FIGURE 48 EUROPE: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT
           TABLE 85 EUROPE: NUMBER OF REGISTERED CAR THERAPY CLINICAL TRIALS, BY COUNTRY, 2015–2020
           TABLE 86 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 87 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 88 EUROPE: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 89 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 90 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2019–2026 (USD MILLION)
           TABLE 91 EUROPE: LEUKOPAKS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 92 EUROPE: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 93 EUROPE: LEUKOPAKS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
           TABLE 94 EUROPE: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION)
             13.3.1 UK
                        13.3.1.1 Rising prevalence of target diseases to drive market growth in the UK
           TABLE 95 UK: KEY MACROINDICATORS
           TABLE 96 UK: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 97 UK: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 98 UK: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2019–2026 (USD THOUSAND)
           TABLE 99 UK: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2019–2026 (USD MILLION)
           TABLE 100 UK: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 101 UK: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION)
             13.3.2 GERMANY
                        13.3.2.1 Increasing research on cancer immunotherapies to drive market growth in Germany
           TABLE 102 GERMANY: KEY MACROINDICATORS
           TABLE 103 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 104 GERMANY: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 105 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2019–2026 (USD THOUSAND)
           TABLE 106 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2019–2026 (USD MILLION)
           TABLE 107 GERMANY: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 108 GERMANY: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION)
             13.3.3 SPAIN
                        13.3.3.1 Rising focus on the development of novel CAR T-cell therapies to drive market growth
           TABLE 109 SPAIN: KEY MACROINDICATORS
           TABLE 110 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 111 SPAIN: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 112 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2019–2026 (USD THOUSAND)
           TABLE 113 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2019–2026 (USD MILLION)
           TABLE 114 SPAIN: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 115 SPAIN: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION)
             13.3.4 REST OF EUROPE
           TABLE 116 ROE: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 117 ROE: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 118 ROE: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 119 ROE: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2019–2026 (USD MILLION)
           TABLE 120 ROE: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 121 ROE: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION)
     13.4 ASIA PACIFIC
           FIGURE 49 APAC: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT
           TABLE 122 APAC: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 123 APAC: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 124 APAC: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 125 APAC: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 126 APAC: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2019–2026 (USD MILLION)
           TABLE 127 APAC: LEUKOPAKS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 128 APAC: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 129 APAC: LEUKOPAKS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
           TABLE 130 APAC: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION)
             13.4.1 CHINA
                        13.4.1.1 Market in China to witness the highest growth during the forecast period
           FIGURE 50 NUMBER OF CAR T-BASED CLINICAL TRIALS REGISTERED IN CHINA (2013–2020)
           TABLE 131 CHINA: KEY MACROINDICATORS
           TABLE 132 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 133 CHINA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 134 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 135 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2019–2026 (USD MILLION)
           TABLE 136 CHINA: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 137 CHINA: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION)
             13.4.2 JAPAN
                        13.4.2.1 Several research activities in Japan are focusing on the development of leukopak-based cell therapies
           TABLE 138 JAPAN: KEY MACROINDICATORS
           TABLE 139 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 140 JAPAN: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 141 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2019–2026 (USD THOUSAND)
           TABLE 142 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2019–2026 (USD MILLION)
           TABLE 143 JAPAN: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 144 JAPAN: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION)
             13.4.3 REST OF ASIA PACIFIC
           TABLE 145 ROAPAC: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 146 ROAPAC: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 147 ROAPAC: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 148 ROAPAC: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2019–2026 (USD MILLION)
           TABLE 149 ROAPAC: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 150 ROAPAC: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION)
     13.5 REST OF THE WORLD
           TABLE 151 ROW: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 152 ROW: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 153 ROW: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 154 ROW: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2019–2026 (USD MILLION)
           TABLE 155 ROW: LEUKOPAKS MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 156 ROW: LEUKOPAKS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
           TABLE 157 ROW: LEUKOPAKS MARKET, BY END USER, 2019–2026 (USD MILLION)

14 COMPETITIVE LANDSCAPE (Page No. - 174)
     14.1 INTRODUCTION
           FIGURE 51 KEY DEVELOPMENTS OF MAJOR PLAYERS, JANUARY 2018–JANUARY 2021
           FIGURE 52 MARKET EVALUATION FRAMEWORK: PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS DOMINATED THE LEUKAPHERESIS MARKET DURING 2018–2021
     14.2 REVENUE SHARE ANALYSIS OF THE TOP 4 MARKET PLAYERS
           FIGURE 53 LEUKAPHERESIS MARKET: REVENUE SHARE ANALYSIS OF THE TOP FOUR MARKET PLAYERS
     14.3 PRODUCT FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE LEUKAPHERESIS AND LEUKOPAKS MARKETS
           TABLE 158 COMPANY PRODUCT FOOTPRINT
           TABLE 159 COMPANY INDUSTRY FOOTPRINT
           TABLE 160 COMPANY APPLICATION FOOTPRINT
           TABLE 161 COMPANY REGION FOOTPRINT
     14.4 LEUKAPHERESIS MARKET SHARE (2020)
           TABLE 162 LEUKAPHERESIS MARKET: DEGREE OF COMPETITION
           FIGURE 54 LEUKAPHERESIS MARKET SHARE, BY KEY PLAYER (2020)
     14.5 LEUKOPAKS MARKET SHARE (2020)
           TABLE 163 LEUKOPAKS MARKET: DEGREE OF COMPETITION
           FIGURE 55 LEUKOPAKS MARKET SHARE, BY KEY PLAYER (2020)
     14.6 COMPETITIVE LEADERSHIP MAPPING (LEUKAPHERESIS MARKET)
     14.7 COMPANY EVALUATION MATRIX DEFINITION & METHODOLOGY
             14.7.1 STARS
             14.7.2 EMERGING LEADERS
             14.7.3 PERVASIVE PLAYERS
             14.7.4 PARTICIPANTS
           FIGURE 56 LEUKAPHERESIS MARKET: COMPANY EVALUATION MATRIX, 2020
     14.8 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (LEUKAPHERESIS MARKET) (2020)
             14.8.1 PROGRESSIVE COMPANIES
             14.8.2 DYNAMIC COMPANIES
             14.8.3 STARTING BLOCKS
             14.8.4 RESPONSIVE COMPANIES
           FIGURE 57 LEUKAPHERESIS MARKET: SME/START-UP COMPANY EVALUATION MATRIX, 2020
     14.9 COMPETITIVE LEADERSHIP MAPPING (LEUKOPAKS MARKET)
             14.9.1 STARS
             14.9.2 EMERGING LEADERS
             14.9.3 PERVASIVE PLAYERS
             14.9.4 PARTICIPANTS
           FIGURE 58 LEUKOPAKS MARKET: COMPANY EVALUATION MATRIX (2020)
     14.10 COMPETITIVE SITUATIONS AND TRENDS
           TABLE 164 PRODUCT LAUNCHES & APPROVALS (JANUARY 2018–JANUARY 2021)
           TABLE 165 DEALS (JANUARY 2018–JANUARY 2021)
           TABLE 166 OTHER DEVELOPMENTS (JANUARY 2018–JANUARY 2021)

15 COMPANY PROFILES (Page No. - 195)
     15.1 KEY PLAYERS (LEUKAPHERESIS MARKET)
             15.1.1 ASAHI KASEI CORPORATION
           TABLE 167 ASAHI KASEI CORPORATION: BUSINESS OVERVIEW
           FIGURE 59 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2020)
             15.1.2 FRESENIUS SE & CO. KGAA
           TABLE 168 FRESENIUS SE & CO. KGAA: BUSINESS OVERVIEW
           FIGURE 60 FRESENIUS MEDICAL CARE: COMPANY SNAPSHOT (2019)
           FIGURE 61 FRESENIUS KABI: COMPANY SNAPSHOT (2019)
             15.1.3 HAEMONETICS CORPORATION
           TABLE 169 HAEMONETICS CORPORATION: BUSINESS OVERVIEW
           FIGURE 62 HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2018)
             15.1.4 TERUMO BCT
           TABLE 170 TERUMO BCT: BUSINESS OVERVIEW
           FIGURE 63 TERUMO BCT: COMPANY SNAPSHOT (2020)
             15.1.5 MACOPHARMA SA
           TABLE 171 MACOPHARMA SA: BUSINESS OVERVIEW
             15.1.6 MILTENYI BIOTEC
           TABLE 172 MILTENYI BIOTEC: BUSINESS OVERVIEW
     15.2 OTHER PLAYERS (LEUKAPHERESIS MARKET)
             15.2.1 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO. LTD.
           TABLE 173 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO. LTD.: BUSINESS OVERVIEW
             15.2.2 MEDICA SPA.
           TABLE 174 MEDICA SPA: BUSINESS OVERVIEW
             15.2.3 PURIBLOOD MEDICAL CO. LTD.
           TABLE 175 PURIBLOOD MEDICAL CO. LTD.: BUSINESS OVERVIEW
             15.2.4 BEIJING ZKSK TECHNOLOGY CO. LTD.
           TABLE 176 BEIJING ZKSK TECHNOLOGY CO. LTD.: BUSINESS OVERVIEW
     15.3 KEY PLAYERS (LEUKOPAKS MARKET)
             15.3.1 ALLCELLS, LLC
           TABLE 177 ALLCELLS, LLC: BUSINESS OVERVIEW
             15.3.2 STEMEXPRESS, LLC
           TABLE 178 STEMEXPRESS, LLC: BUSINESS OVERVIEW
             15.3.3 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
           TABLE 179 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW
           FIGURE 64 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2019)
           FIGURE 65 HEMACARE CORPORATION: COMPANY SNAPSHOT (2018)
             15.3.4 LONZA GROUP AG
           TABLE 180 LONZA GROUP AG: BUSINESS OVERVIEW
           FIGURE 66 LONZA GROUP AG: COMPANY SNAPSHOT (2019)
     15.4 OTHER PLAYERS (LEUKOPAKS MARKET)
             15.4.1 CALTAG MEDSYSTEMS LIMITED
           TABLE 181 CALTAG MEDSYSTEMS LIMITED: BUSINESS OVERVIEW
             15.4.2 ZENBIO, INC.
           TABLE 182 ZENBIO, INC.: BUSINESS OVERVIEW
             15.4.3 PRECISION FOR MEDICINE, INC.
           TABLE 183 PRECISION FOR MEDICINE, INC.: BUSINESS OVERVIEW
             15.4.4 BIOIVT
           TABLE 184 BIOIVT: BUSINESS OVERVIEW
             15.4.5 DISCOVERY LIFE SCIENCES
           TABLE 185 DISCOVERY LIFE SCIENCES: BUSINESS OVERVIEW
             15.4.6 INTELLIGENT TISSUE GROUP

16 APPENDIX (Page No. - 237)
     16.1 DISCUSSION GUIDE
     16.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     16.3 AVAILABLE CUSTOMIZATIONS
     16.4 RELATED REPORTS
     16.5 AUTHOR DETAILS

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

Secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Business, Factiva, and D&B Hoovers), white papers, annual reports, companies house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the leukaphereis and leukopaks market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The leukapheresis and leukopaks market comprises several stakeholders such as device manufacturers and distributors and regulatory organizations. The demand side of this market is characterized by  hospitals & clinics, pharmaceutical and biotechnology companies, healthcare service providers (including hospitals and transfusion centers), blood component providers & blood centers, contract research organizations (CROs), and academic and research institutes.

Various primary sources from both, the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.

Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.

A breakdown of the primary respondents for leukopaks market is provided below:

Leukapheresis Market   Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (segmental analysis of major segments) and top-down approach (assessment of utilization/adoption/penetration trends, by product, by application, by indication, by end user and by region).

Data Triangulation

After arriving at the market size, the total leukapheresis products and leukopaks market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments & subsegments, data triangulation, and market breakdown procedures were employed, wherever applicable.

Objectives of the Study

  • To define, describe, analyze, and forecast the size of the leukapheresis products and leukopaks market on the basis of product, application, indication, end user and region.
  • To provide detailed information on the major factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges)
  • To strategically analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
  • To forecast the size of the market segments with respect to North America, Europe, Asia Pacific, and Rest of the World.
  • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies.
  • To track and analyze competitive developments such as product launches, expansions, partnerships, agreements, collaborations, acquisitions and other developments in the market.
  • To benchmark players within the leukapheresis products and leukopaks market using the Competitive Leadership Mapping framework which analyzes market players on various parameters within the broad categories of business and product strategy.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players

Geographic Analysis

  • Further breakdown of the Rest of Asia Pacific leukapheresis products and leukopaks market into South Korea, New Zealand, and other countries
  • Further breakdown of Rest of the World into Latin America and Middle East & Africa.
COVID-19

Get in-depth analysis of the COVID-19 impact on the Leukapheresis Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Leukapheresis Market

Request For Special Pricing
Report Code
MD 6538
Published ON
Apr, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Leukapheresis Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved